Evidence map›Paper›PMID 35467745›Full record

ArticleJAMA neurology2022

Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US.

Joshua R Ehrlich, Jenna Goldstein, Bonnie K Swenor, Heather Whitson, Kenneth M Langa, Phillip Veliz

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in JAMA neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 4 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Visual field defects in dementia: A scoping review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Pooled it
  2. Dual sensory impairment: Global prevalence, future projections, and its association with cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Stratifying dementia risk factors: A prediction model and hypothesis-driven analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Article
  13. Resistance and resilience to Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Joshua R EhrlichDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor.
Jenna GoldsteinUniversity of Michigan Medical School, Ann Arbor.
Bonnie K SwenorWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Heather WhitsonGeriatric Medicine Division, Duke University School of Medicine, Durham, North Carolina.
Kenneth M LangaInstitute for Social Research, University of Michigan, Ann Arbor.
Phillip VelizInstitute for Social Research, University of Michigan, Ann Arbor.
University of Michigan–Ann Arbor · USDurham VA Health Care System · USJohns Hopkins University · US

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
Research Education Component CoreP30AG072958 · NIA · DUKE UNIVERSITY · PI GWENN A GARDEN, Heather E. Whitson · 2021 to 2026
$24.1M
Pilot CoreP30AG066582 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Julie PW Bynum · 2020 to 2026
$7.2M
Dementia Prevalence over Time: Proximate Causes and ConsequencesR01AG053972 · NIA · RAND CORPORATION · PI HURD, MICHAEL D · 2016 to 2021
$4.9M
Understanding Alzheimer's Disease in the Context of the AgingR01AG062623 · NIA · DUKE UNIVERSITY · PI OUKRAINTSEVA, SVETLANA V. · 2019 to 2023
$3.6M
Cognitive Changes and Brain Connectivity in Age-Related Macular DegenerationR01AG043438 · NIA · DUKE UNIVERSITY · PI WHITSON, HEATHER E. · 2013 to 2017
$2.1M
Addressing Low Vision due to Severe Peripheral Field Loss: Development and Validation of a Patient-Centered Outcome MeasureK23EY027848 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI EHRLICH, JOSHUA ROBERT · 2017 to 2021
$1.2M
Vision Loss and Cognition: Testing the sensory consequence hypothesisK01AG052640 · NIA · JOHNS HOPKINS UNIVERSITY · PI SWENOR, BONNIELIN · 2017 to 2021
$834k
NEI NIH HHS K23 EY027848NIA NIH HHS K01 AG052640NIA NIH HHS P30 AG024824NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066582NIA NIH HHS P30 AG072958NIA NIH HHS R01 AG043438NIA NIH HHS R01 AG053972NIA NIH HHS R01 AG062623NIA NIH HHS U01 AG009740
6 · The paper itself

Abstract

Importance: Dementia prevention is a high priority, given the large impact of dementia on the well-being of individuals and society. The number of older adults with dementia in the US and globally is projected to increase as a result of population aging and growth. Thus, it is vital to identify potentially modifiable dementia risk factors. Vision impairment has been identified as a risk factor for accelerated cognitive decline and incident dementia. An estimated 90% of vision impairment is preventable or has yet to be treated. Nevertheless, vision impairment has not been included in the dominant life-course models of dementia risk factors used to shape public health policy and research priorities. Objective: To strengthen an existing model of potentially modifiable dementia risk factors through the inclusion of vision impairment and to estimate the contributions of those risk factors in the US population. Design, Setting, and Participants: Population-based, cross-sectional study using data from the 2018 round of the Health and Retirement Study. Analyses were conducted from March 11 through September 24, 2021. The study population was a probability sample of US adults aged 50 years and older. Exposures: Potentially modifiable dementia risk factors, including vision impairment. Main Outcomes and Measures: The estimated population attributable fractions (PAFs) of dementia associated with vision impairment and other dementia risk factors were calculated. The PAF represents the number of cases of dementia that would potentially be prevented if a risk factor were eliminated. Results: The probability sample from the Health and Retirement Study included 16 690 participants (weighted demographic characteristics: 54.0% female, 52.0% age ≥65, 10.6% Black, 80% White, and 9.2% identified as other [including American Indian or Alaska Native, Asian, and Hawiian Native or Pacific Islander, although specific data were not available]). The 12 dementia risk factors in the PAF model were associated with an estimated 62.4% of dementia cases in the US. The risk factor with the highest weighted PAF for dementia was hypertension (12.4%). The PAF of vision impairment was 1.8%, suggesting that more than 100 000 prevalent dementia cases in the US could potentially have been prevented through healthy vision. Conclusions and Relevance: Existing life-course models of potentially modifiable dementia risk factors may consider including vision impairment. Since a large majority of vision impairment can be treated with cost-effective but underused interventions, this may represent a viable target for future interventional research that aims to slow cognitive decline and prevent incident dementia.

Indexed as

Cognitive DysfunctionDementiaAgedAgingCross-Sectional StudiesFemaleHumansMaleMiddle AgedRisk Factors

Identifiers

PMID35467745
PMCPMC9039828
OpenAlexW4224438955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.